Streptococcus pneumoniae News and Research

RSS
Streptococcus pneumoniae, or Pneumococcus, is a very common bacterial infection in both industrialized and developing countries. In particular, young children and the elderly represent high-risk populations of developing pneumococcal infections. According to the WHO, the bacterium kills up to one million children under the age of five years each year worldwide. It accounts for many Bacterial Meningitis cases in adults and it is the most common cause of Bacteraemia, Pneumonia, Meningitis and Otitis media in young children.
High risk of serious complications or death in children with SP-HUS

High risk of serious complications or death in children with SP-HUS

Isconova expands Matrix M collaboration with Genocea to treat infectious diseases

Isconova expands Matrix M collaboration with Genocea to treat infectious diseases

FDA issues 90-day extension for Pfizer's Prevnar 13 sBLA to treat pneumonia in adults

FDA issues 90-day extension for Pfizer's Prevnar 13 sBLA to treat pneumonia in adults

Final Atlantis space trip may open new era of research into infectious diseases

Final Atlantis space trip may open new era of research into infectious diseases

Recombinant attenuated Salmonella vaccines hold promise against infectious diseases

Recombinant attenuated Salmonella vaccines hold promise against infectious diseases

Cempra to present solithromycin Phase 1 study data at ECCMID/ICC meeting

Cempra to present solithromycin Phase 1 study data at ECCMID/ICC meeting

Furiex Pharmaceuticals to present two JNJ-Q2 antibiotic abstracts at ECCMID/ ICC congress

Furiex Pharmaceuticals to present two JNJ-Q2 antibiotic abstracts at ECCMID/ ICC congress

Viral infection likely to encourage pneumonia spread

Viral infection likely to encourage pneumonia spread

FDA says no cause for alarm on vaccines for meningitis and pneumonia

FDA says no cause for alarm on vaccines for meningitis and pneumonia

Sinovac submits clinical trial application for 13-valent pneumococcal conjugate vaccine to China SFDA

Sinovac submits clinical trial application for 13-valent pneumococcal conjugate vaccine to China SFDA

Positive results from Trius torezolid Phase 1 lung study

Positive results from Trius torezolid Phase 1 lung study

Experimental vaccine appears to protect against pneumonia

Experimental vaccine appears to protect against pneumonia

Researchers develop new pneumococcal vaccine through novel discovery approach

Researchers develop new pneumococcal vaccine through novel discovery approach

Pneumococcal vaccine officially rolled out in Kenya

Pneumococcal vaccine officially rolled out in Kenya

Scientists use full genome sequencing to identify precise steps in molecular evolution of S. pneumoniae

Scientists use full genome sequencing to identify precise steps in molecular evolution of S. pneumoniae

Bill and Melinda Gates Foundation grants $1.5million to Liverpool University for bacterial study

Bill and Melinda Gates Foundation grants $1.5million to Liverpool University for bacterial study

Genocea announces close of $35 million Series B venture financing round

Genocea announces close of $35 million Series B venture financing round

Pfizer seeks FDA and EMA approval for expanded use of Prevnar 13 for pneumococcal disease

Pfizer seeks FDA and EMA approval for expanded use of Prevnar 13 for pneumococcal disease

Researchers recommend 'watchful waiting' over antibiotic treatment for many children with ear infections

Researchers recommend 'watchful waiting' over antibiotic treatment for many children with ear infections

Otoscopic exams critical for accurate diagnosis of ear infections in children

Otoscopic exams critical for accurate diagnosis of ear infections in children

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.